STOCK TITAN
  1. Home
  2. News
  3. SGEN

Seagen Inc - sgen STOCK NEWS

Welcome to our dedicated news page for Seagen (Ticker: sgen), a resource for investors and traders seeking the latest updates and insights on Seagen.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Seagen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Seagen's position in the market.

News
Pfizer Completes Acquisition of Seagen
Rhea-AI Summary
Pfizer Inc. (NYSE: PFE) has completed the acquisition of Seagen Inc. (NASDAQ: SGEN) for $43 billion, solidifying its position as a leading oncology company. The acquisition brings Seagen's world-leading Antibody-Drug Conjugate (ADC) technology and four in-line medicines to Pfizer's oncology portfolio. Dr. Albert Bourla, Pfizer's Chairman and CEO, emphasizes the company's commitment to delivering breakthrough treatments for cancer, with Oncology expected to be a significant growth driver for Pfizer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.99%
Tags
acquisition
-
News
Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen
Rhea-AI Summary
Pfizer Inc. (PFE) is set to close the acquisition of Seagen Inc. (SGEN) on December 14, 2023, after receiving all required regulatory approvals. The company also announced changes in its commercial organization to incorporate Seagen and improve focus, speed, and execution. Pfizer will host an analyst and investor call to discuss the acquisition, new commercial organization, and provide full-year 2024 financial guidance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
acquisition
-
News
ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin Lymphoma
Rhea-AI Summary
Seagen Inc. (NASDAQ: SGEN) announced encouraging results from a Phase 2 study evaluating ADCETRIS in combination with nivolumab and standard chemotherapy agents as first-line treatment for early and advanced stage classical Hodgkin lymphoma. The investigational regimen showed a clinically meaningful progression-free survival rate, favorable clinical outcomes, and a consistent safety profile, with no new safety signals observed. The study demonstrated an overall response and complete response rate of 98% and 93% respectively in early-stage cHL patients, and an overall response and complete response rate of 95% and 89% respectively in advanced-stage cHL patients. The PFS rate at 24 months for advanced-stage cHL patients was 88%. ADCETRIS has been a proven foundation of care for CD30-expressing lymphomas globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.2%
Tags
clinical trial
News
TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improves Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer
Rhea-AI Summary
Seagen Inc. (Nasdaq: SGEN) announced positive data from the Phase 3 HER2CLIMB-02 clinical trial of TUKYSA® (tucatinib) in combination with ado-trastuzumab emtansine for patients with HER2-positive breast cancer. The combination showed a significant improvement in progression-free survival and objective response rate, with manageable adverse events. TUKYSA is already approved by the FDA for third-line metastatic HER2-positive breast cancer, and the trial results reinforce its clinical activity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.01%
Tags
none
-
News
FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Rhea-AI Summary
Seagen Inc. (SGEN) and Astellas Pharma Inc. (4503) announced that the FDA accepted for priority review a supplemental Biologics License Application for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as a combination therapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer. The combination significantly extended overall survival and progression-free survival vs standard platinum-containing chemotherapy. If approved, it would be the first and only antibody-drug conjugate plus PD-1 inhibitor treatment alternative to chemotherapy in this patient population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
none
-
News
Seagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Rhea-AI Summary
Seagen Inc. presented Phase 2 data for ADCETRIS in combination with pembrolizumab in non-small cell lung cancer and melanoma. The combination showed objective response rates of 8% and 14% in NSCLC, and 18% and 22% in melanoma. Disease control rates were 67% and 72% in NSCLC, and 71% and 80% in melanoma. The safety profile was consistent with previous studies. Preclinical data was also presented for SGN-35T, a novel ADC with potential for improved tolerability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.1%
Tags
clinical trial
News
New Data for ADCETRIS® (brentuximab vedotin) with Immunotherapy Combination in Hodgkin Lymphoma to be Featured at 2023 ASH Annual Meeting, and Seagen to Unveil Novel CD30-Directed Antibody-Drug Conjugate
Rhea-AI Summary
Seagen Inc. (NASDAQ: SGEN) announced that updated Phase 2 data for ADCETRIS in combination with nivolumab in early and advanced stage classical Hodgkin lymphoma will be presented at the 65th American Society of Hematology (ASH) Annual Meeting. The data will include 12- and 24-month progression free survival rates. Additionally, preclinical data for the investigational antibody-drug conjugate SGN-35C will also be presented.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.2%
Tags
none
-
News
Seagen Third Quarter 2023 Financial Results Reflect Strong Product Sales Growth, and Significant Portfolio and Pipeline Progress
Rhea-AI Summary
Seagen Inc. reported record net product sales of $571 million in 3Q23, a 33% increase over 3Q22. PADCEV® in combination with Keytruda® demonstrated a near doubling of median overall survival in first-line metastatic urothelial cancer. The proposed Pfizer transaction is on-track to close in late-2023 or early-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
earnings
-
News
TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial
Rhea-AI Summary
Seagen Inc. and Genmab A/S announced positive results from the Phase 3 innovaTV 301 trial, showing that TIVDAK demonstrated a 30% reduction in the risk of death in recurrent or metastatic cervical cancer patients compared to chemotherapy. TIVDAK also showed significant improvements in overall survival, progression-free survival, and objective response rate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
News
Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer
Rhea-AI Summary
Seagen and Astellas announce positive results from Phase 3 clinical trial for enfortumab vedotin plus pembrolizumab in urothelial cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock SGEN logo
Seagen Inc

NYSE:SGEN

SGEN Rankings

N/A Ranked by Market Cap
#252 Ranked by Stock Gains
N/A Ranked by Dividends

SGEN Stock Data

43.15B
129.83M
0.81%
88.83%
5.08%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Bothell

About SGEN

seattle genetics, co-founded by clay siegall, is a biotechnology company leading the field of antibody-drug conjugates (adcs) for the treatment of cancer. our technology is designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. our lead program, adcetris® (brentuximab vedotin), is the first in a new class of adcs and, in collaboration with takeda pharmaceutical company limited, is approved in more than 55 countries. to expand on the adcetris opportunity, we are conducting a broad clinical development program to evaluate its therapeutic potential in a range of other lymphoma and non-lymphoma settings. seattle genetics is also advancing a robust pipeline of clinical-stage programs, including sgn-cd19a, sgn-cd33a, sgn-liv1a, sgn-cd70a, asg-22me, asg-15me and sea-cd40. seattle genetics has collaborations for its adc technology with a number of leading biotechnology and pharmaceutical companies, including abbvie, agensys